Eyenovia Inc. (EYEN) shares surged on Monday after the company announced the launch of a new FDA-approved ophthalmic drug, APP13007, developed in collaboration with Formosa Pharmaceuticals. This innovative drug, the first of its kind using clobetasol propionate, offers a convenient and cost-effective treatment for postoperative inflammation and pain following eye surgery.